
Advertise on podcast: The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes
Rating
3from
This podcast has
206 episodes
Language
EnglishPublisher
BZ GroupExplicit
No
Date created
2026/03/14
Latest episode
2026/11/13
Average duration
16 min.
Release period
2 days
Description
Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.
Unlock The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes podcast
Daily Roundup | enGene Plans Bladder Cancer Filing & Mirum’s Second Hepatitis D Phase 3 Win
2026/11/13
enGene plans to start its FDA filing for detalimogene voraplasmid in bladder cancer by year-end after longer follow-up in a single-arm trial. Mirum’s brelovitug met the primary endpoint in a second Phase 3 hepatitis D trial, adding evidence for its planned US filing. Also covered: BioNTech’s $205 million deal for Scholar Rock’s priority review voucher, PepGen’s PGN-EDODM1 splicing data in myotonic dystrophy type 1, Oyster Therapeutics’ financing for its tau program, and Summit’s November 14 FDA goal date for ivonescimab plus chemotherapy in EGFR-mutated lung cancer. This is the delayed November 11, 2026 edition, released November 12.
Alex Mercer and Maya Patel host.
Sources
enGene — LEGEND and filing plan
https://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspx
Mirum — AZURE-4 and filing plan
https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-AZURE-4-Phase-3-Study-and-Highlights-Long-Term-Brelovitug-Data-Presented-at-AASLD/default.aspx
BioNTech — priority review voucher agreement
https://www.biontech.com/us/en/home/mediaroom/news/statements/2026/11/BioNTech-to-Acquire-US-FDA-Priority-Review-Voucher.html
PepGen — FREEDOM2-DM1 and partial clinical hold
https://investors.pepgen.com/node/9531/html
4BIO Capital — Oyster Therapeutics financing
https://www.4biocapital.com/single-post/oyster-series-a
Summit Therapeutics — HARMONi and FDA goal date
https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/
Daily Roundup | Bayer's Stroke Approval Puts Bleeding Risk in Focus & Beam Nears Sickle Cell Filing
2026/11/12
Delayed release of the November 10, 2026 edition. News reflects the November 10 research cutoff.
Bayer's Sunharbo (asundexian) wins FDA approval for stroke prevention, with bleeding risks shaping patient selection. Beam's risto-cel meets its pivotal sickle cell goal, but a year-end filing could precede detailed public results. Lilly's Foundayo (orforglipron) sleep apnea data, Boehringer and Zealand's survodutide safety result, and the FDA's GLP-1 vision-warning action put benefit and tolerability in focus. Also: Novocure's Optune Mya setback in lung-cancer brain metastases, EMD Serono's pimicotinib approval for tenosynovial giant cell tumor, Compass's COMP360 depression filing, and argenx's deal for Unnatural Products.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Week in Review | Vir's Hepatitis Delta Result & CVS Split Plan: Full Recap
2026/11/10
In this full November 2–8 recap, 44% of treated patients in Vir's hepatitis delta trial met the Phase 3 primary endpoint, with an important difference in when the comparison groups were measured. CVS plans to separate its retail pharmacies and MinuteClinic from Aetna and Caremark, subject to conditions. Alex and Maya also examine HOVON 150 in IDH1-mutated leukemia, FDA's Zolgensma safety investigation, cardiovascular data and the week's deals and manufacturing news — and what the evidence does and does not show.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Daily Roundup | ANI's Recommended Egetis Offer & BHB-1893 Heart Study: Most End on Starting Dose
2026/11/07
ANI Pharmaceuticals made a recommended cash offer of about 5.3 billion kronor for Egetis Therapeutics, maker of Emcitate (tiratricol); the acceptance period is expected to open around November 20. Braveheart and Hengrui reported 52-week open-label data, with no comparison group, for oral BHB-1893 in adults with symptomatic obstructive HCM: 33 of 42 had a provoked gradient below 30 mmHg and 24 ended on the starting dose. Also: Amgen's real-world Repatha (evolocumab) vs. ezetimibe study; Lilly and Hims & Hers on Zepbound (tirzepatide) and Foundayo (orforglipron) self-pay access; Agios R&D role cuts; Moderna's norovirus cohort decision; and its Q3 revenue and raised outlook. This is the original Friday, November 6 edition, released late.
Daily Roundup | Rybrevant Faspro Gets Accelerated FDA Nod in Head and Neck Cancer & Tibsovo Lifts EFS in Fit AML
2026/11/07
J&J's Rybrevant Faspro (amivantamab) won accelerated FDA approval in later-line head and neck cancer on a 42% single-arm response rate. A HOVON trial adding Tibsovo (ivosidenib) to intensive chemotherapy in IDH1-mutated AML showed a large interim event-free survival gain, though overall survival is not reported. The daily roundup covers ASH detail on Genmab and AbbVie's epcoritamab plus lenalidomide in lymphoma and Pfizer's Elrexfio (elranatamab) in myeloma, Boehringer Ingelheim's staged six-program deal with SBP Group, and the FDA's Nov 6 Zolgensma cancer-risk alert in spinal muscular atrophy. Akebia's VOCAL trial of Vafseo (vadadustat) in dialysis anemia closes this original November 5 edition, released on a delayed schedule.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Daily Roundup | CVS plans to split pharmacies from Aetna and Caremark & AbbVie licenses Nxera's IBD drug
2026/11/07
CVS Health plans to split into two public companies, separating about 9,000 pharmacies from Aetna and Caremark, targeting the first half of 2028. This delayed November 4 edition also covers AbbVie's IBD license for Nxera's gut-targeted NXE0033744: $100 million upfront, up to $1.37 billion in milestones, and no IBD efficacy results in the announcement. In the roundup: FDA priority review for BeOne's Brukinsa (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, and Pfizer's November 3 snapshot of discontinued obesity, PAH and KRAS programs. Plus Novo Nordisk's diverging Q3 operating profit measures and FDA Breakthrough Therapy designation for Idorsia's daridorexant in pediatric insomnia.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Daily Roundup | Fresenius gains access to up to 37 biosimilar candidates via WuXi & Supernus-Indivior merger closes
2026/11/07
Fresenius gains exclusive access to up to 37 biosimilar candidates through WuXi Biologics, with initial development expected on biosimilars of polatuzumab vedotin and teprotumumab. Supernus and Indivior complete their merger, leaving former Indivior holders with about 56.5% of Supernus, Inc., while a separate $1 billion dividend is partly funded by a loan to the combined company. In neurology, Bright Minds reports an FDA partial hold on a planned BMB-101 Phase 2 study, Tiziana reports INFORM-MS data for foralumab, and Novartis ends a BrainTransporter deal with BioArctic. This delayed November 2 edition cites Samsung Biologics' later November 5 definitive figures: 97.66% of PolyPeptide's issued share capital and voting rights tendered.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Daily Roundup | Servier Drug Misses Becker Trial & Karyopharm Files Chapter 11
2026/11/05
Servier's sevasemten missed its pivotal Becker muscular dystrophy trial, while Karyopharm filed Chapter 11 and proposed an Ayrmid deal around XPOVIO. This delayed November 3, 2026 edition reports dated developments: 'today' means November 3 and 'Monday' November 2. Also covered: uniQure's AMT-130 application, Teva's TOPAS-MSA stop, FDA potency guidance, InventisBio's psoriasis results, Recursion's REC-4881 data, Dr. Reddy's tentative lenacapavir approval reported by CHAI, Rhythm's LG Chem amendment and Pfizer's forecast.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Week in Review | Estrogen Patch Boxed Warnings Revised, Novartis Writes Down Del-Desiran & Acumen Ends Sabirnetug
2026/11/03
November 1, 2026 edition — delayed release. This recap covers October 26–30; its dated week-ahead items reflect preparation-time previews, not subsequently reported results. The FDA removed the cardiovascular disease, breast cancer and probable dementia risk statements from the boxed warnings on the Minivelle, Vivelle and Vivelle-Dot estradiol patches; Minivelle keeps its endometrial cancer box, and all three remain prescription products. Novartis took a $1.94 billion partial, noncash impairment on del-desiran after September's HARBOR miss, and Acumen ended sabirnetug after its Phase 2 Alzheimer's trial reduced plaque but missed on cognition and function. We also cover the FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide), Lilly's retatrutide head-to-head against Ozempic (semaglutide), Genmab's petosemtamab survival result, Ilumya's psoriatic arthritis approval and Agios's new mitapivat decision date. Then the dated week ahead: Pfizer, Novo Nordisk, Recursion, SITC and AHA.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
ESMO 2026 Debrief: A 12-Week Checkpoint Dosing Trial Stopped Early & Ivonescimab Beats Imfinzi on Survival in Biliary Cancer
2026/11/02
The Pharma Closeout's ESMO 2026 Debrief brings you the readouts from the European Society for Medical Oncology congress in Madrid that matter, what they change, and what to watch next, with one thread running through them: how much checkpoint therapy is enough. MOIO, a French trial that spaced checkpoint-inhibitor doses to every 12 weeks in patients already responding, was stopped early on its monitoring committee's recommendation. Around bladder surgery, Merck's KEYNOTE-866 and Bristol Myers Squibb's ENERGIZE both missed event-free survival in cisplatin-eligible patients, while VOLGA won in patients ineligible for or declining cisplatin, and final PEARLS survival for adjuvant Keytruda in lung cancer missed significance. Then mismatch repair-deficient tumors, with a correction on GSK's AZUR-1 numbers; Akeso and Summit's ivonescimab beating AstraZeneca's Imfinzi on survival in biliary tract cancer at an interim analysis; Tagrisso plus Orpathys in two lines of lung cancer; Amgen's Imdelltra and a rival DLL3 drug in small-cell lung cancer; six-year NATALEE survival for Novartis's Kisqali; androgen-receptor drugs moving earlier in prostate cancer; and cancer vaccines, led by Merck and Moderna's intismeran. Plus what to watch: INTerpath-001's full results, slated for The New England Journal of Medicine on November 11, and the November 14 FDA goal date for ivonescimab in EGFR-mutated lung cancer.
0:00 Cold open and introduction
1:03 Story of the Congress: how much checkpoint is enough (MOIO, KEYNOTE-866, ENERGIZE, VOLGA, PEARLS)
5:45 Mismatch repair-deficient tumors: KEYNOTE-C93, TroFuse-005, the AZUR-1 correction and CheckMate 8HW
9:19 Biliary tract cancer: ivonescimab beats Imfinzi in HARMONi-GI1
10:43 Lung cancer: SAFFRON, SANOVO, sigvotatug vedotin and PERSEE
13:18 Small-cell lung cancer: DeLLphi-305, ASTRIDE and IDE849
14:37 Breast cancer: NATALEE at six years and postMONARCH
15:53 Prostate cancer: PROTEUS, DASL-HiCaP and J&J's RIPTAC
17:50 Cancer vaccines: intismeran, ELI-002 7P and DOVACC
19:08 What to watch: INTerpath-001 in NEJM and the ivonescimab FDA decision
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
Daily Roundup | Acumen Ends Alzheimer's Antibody After Phase 2 Miss & Inovio's Voceryq Wins Accelerated Approval
2026/11/01
October 30 edition — delayed release on November 1. References to today and Friday in the audio refer to October 30.
Acumen ends sabirnetug after a Phase 2 Alzheimer's trial lowered amyloid but missed on cognition and function, and Inovio's Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) won accelerated approval for adult recurrent respiratory papillomatosis, with benefit yet to be verified. Sun Pharma's Ilumya (tildrakizumab-asmn) is approved for active psoriatic arthritis, Agios' mitapivat sickle cell action date moved to February 1, 2027, and NRx says FDA approved its generic preservative-free ketamine. Dren Bio raised $350 million for dibotatug, and Setara $90 million for STAR-0871 in CMT2C. Regeneron's Eylea (aflibercept) and Sanofi's Dupixent (dupilumab) quarters and Nxera's operating-profit swing close it out.
Daily Roundup | Iovance Lung Data Points to a Subgroup & Ono Plans New Pain Studies After 3 Misses
2026/10/30
October 29, 2026 edition, released October 30. The audio reflects the October 29 roundup; the INO-3107 watch refers to an October 30 FDA target date, not an announced decision.
Iovance's lifileucel produced responses in 17 of 69 previously treated non-squamous lung cancer patients who received at least 10 billion viable cells. A new cohort, POSITILITY, will select patients up front using a subgroup profile found in a retrospective analysis. Ono's ONO-1110 missed primary endpoints in three Phase 2 pain studies; Ono is planning further pain studies based on prespecified subgroup and post hoc signals, and plans no further studies in depression or social anxiety. The daily roundup covers BMS ending Prothena's PRX019 license, Rafael's remibetadex NDA in Niemann-Pick type C after a Phase 3 primary-endpoint miss, a BioMarin Fabry license, Alnylam's TRITON-CM expansion, Lilly and Merck third quarters, and a Labor Department PBM disclosure rule.
Daily Roundup | Genmab's Cancer Survival Gain & Lilly's Retatrutide Dose Trade-Off
2026/10/29
This is the October 28 edition of The Pharma Closeout, released October 29.
Genmab's investigational petosemtamab combination improves survival against pembrolizumab alone in a first-line head-and-neck cancer trial, while Lilly's retatrutide raises a dose-choice question after greater weight loss and more adverse-event discontinuations than Ozempic (semaglutide) 2 mg in type 2 diabetes. Geron stops imetelstat's myelofibrosis trial; AbbVie files etentamig for multiple myeloma using previously reported CERVINO results; and Replimune reports early launch activity for TUDRIQEV (vusolimogene oderparepvec-wtpg) in melanoma. FDA's draft individualized gene-editing framework, CMS's planned gene-therapy access expansion and HHS's proposed conditional peptide-compounding policy remain distinct developments. GSK's sales mix shifts toward specialty medicines, and FDA staff questions set up the October 30 advisory committee on Sydnexis's atropine for pediatric myopia.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
Daily Roundup | Artiva Ends AlloNK, Cuts 94% of Staff & Ferring Agrees to Buy Gameto
2026/10/28
Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up to $1.3825 billion subject to milestones, before Fertilo's pivotal fertility trial reports. Pfizer's ELREXFIO (elranatamab) meets a Phase 3 myeloma goal with higher rates of severe infections; AstraZeneca and Daiichi Sankyo gain EU approval for Enhertu (trastuzumab deruxtecan) in postoperative HER2-positive early breast cancer; Novartis discontinues remibrutinib in generalized myasthenia gravis for futility. Also: Teva closes its BioXcel asset deal for IGALMI (dexmedetomidine) and the pending at-home BXCL501 program; Vanda's NEREUS (tradipitant) reduces vomiting in a single-dose semaglutide challenge; and Kiniksa raises its ARCALYST (rilonacept) sales forecast.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
Daily Roundup | BioNTech/DualityBio Breast ADC Gain Called Modest & Merck's sac-TMT Survival Edge Under FDA Review
2026/10/27
October 26, 2026 edition, released October 27. Recorded October 26: references to today mean October 26, and tomorrow means October 27.
BioNTech and DualityBio's breast cancer ADC beat chemo in Phase 3, yet the companies call the gain modest. Merck and Kelun's sac-TMT showed interim median overall survival of 19.0 vs 12.1 months in endometrial cancer after platinum and immunotherapy and is under FDA priority review. Also: Keytruda (pembrolizumab) alone in first-line dMMR endometrial cancer; FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) for adults with metastatic, androgen pathway modulation-naive or -sensitive prostate cancer with HRR mutations detected by an FDA-authorized test; BMS/SystImmune's iza-bren in EGFR-mutated lung cancer; GSK/Hansoh's ris-rez in osteosarcoma; and Corxel US/Amanat's proposed deal that would help fund oral GLP-1 CX11.
Sources:- SEC (BioNTech Exhibit 99.1): DYNASTY-Breast02 topline Phase 3 results for trastuzumab pamirtecan — October 26, 2026 — https://www.sec.gov/Archives/edgar/data/0001776985/000177698526000074/a991261025_bntxdbxtpamxtop.htm- FDA: Approval of fam-trastuzumab deruxtecan-nxki in HR-positive HER2-low or HER2-ultralow metastatic breast cancer — January 2025 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2- Merck: TroFuse-005 sacituzumab tirumotecan endometrial results and FDA priority review — October 26, 2026 — https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/- Merck: KEYNOTE-C93 Keytruda monotherapy in dMMR endometrial cancer — October 26, 2026 — https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-43-for-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient/- FDA: Approval of talazoparib with enzalutamide in metastatic androgen pathway modulation-naive or -sensitive prostate cancer — October 26, 2026 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive- Bristol Myers Squibb: PANKU-Lung01 Phase 3 results for izalontamab brengitecan — October 26, 2026 — https://news.bms.com/news/corporate-financial/2026/Izalontamab-Brengitecan-Iza-Bren-Doubles-Median-Progression-Free-Survival-in-Patients-with-Previously-Treated-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Compared-to-Chemotherapy-in-the-Phase-3-PANKU-Lung01-Study/default.aspx- FDA: Approval of amivantamab-vmjw with carboplatin and pemetrexed after EGFR TKI — September 19, 2024 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19- GSK: ARTEMIS-011 ris-rez in relapsed osteosarcoma in China — October 26, 2026 — https://www.gsk.com/en-gb/media/press-releases/ris-rez-reduced-risk-of-disease-progression-or-death-by-67-versus-chemotherapy-in-patients-with-relapsed-osteosarcoma-in-china/- SEC (Exhibit 99.1): Corxel and Amanat proposed business combination and financing — October 26, 2026 — https://www.sec.gov/Archives/edgar/data/2112457/000121390026112236/ea030895401ex99-1.htm- FDA: Approval of talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer — June 20, 2023 — https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate
Podcast reviews
Read The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes podcast reviews
Adrian8765 2026/09/07
AI voices are terrible
The robot readers do not pronounce things correctly and do pauses where they don’t belong making this nearly unlistenable.
Podcast sponsorship advertising
Start advertising on The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes relevant audience podcasts
You may also like to advertise on these Podcasts

4.930902000
The Quote of the Day Show | Daily Motivational Talks
Sean Croxton

4.6432911273
Verdict with Ted Cruz
Premiere Networks

4.762612000
The Lawfare Podcast
The Lawfare Institute

4.7278922000
The Matt Walsh Show
The Daily Wire

4.818422000
The Cabral Concept
Dr. Stephen Cabral

4.6314191097
Wow in the World
Tinkercast

4.8121251000
Mind Pump: Raw Fitness Truth
Sal Di Stefano, Adam Schafer, Justin Andrews, Doug Egge

4.6620122000
The Dan Bongino Show
Cumulus Podcast Network | Dan Bongino

4.8167522000
The GaryVee Audio Experience
Gary Vaynerchuk

4.838332000
Entrepreneurs on Fire
John Lee Dumas of EOFire